TIDMLPX 
 
RNS Number : 5219F 
Lipoxen PLC 
14 January 2010 
 

+--------------------------------------+--------------------------------------+ 
| FOR IMMEDIATE RELEASE                |                      14 JANUARY 2010 | 
+--------------------------------------+--------------------------------------+ 
 
 
Lipoxen plc 
('Lipoxen' or 'the Company') 
 
 
Lipoxen's Bio-Polymer Technology Granted Important US Patent 
 
 
- Extends life of the use of this natural polymer and extends cover in the 
World's largest market - 
 
 
Lipoxen plc (AIM: LPX), a bio-pharmaceutical company specialising in the 
development of high-value differentiated biologicals, vaccines and siRNA 
delivery, announces today that it has been granted a new US patent for its 
PolyXen technology.This technology is based on polysialic acid (PSA), (a polymer 
occurring naturally in humans) which extends a protein's active life, is 
biodegradable, non-immunogenic and non-toxic, and which is also therefore 
expected to avoid the toxicity attributed to polyethylene glycol in PEGylated 
protein drug candidates. 
 
 
Polysialylation of therapeutic proteins i.e. the attachment of PSA on these 
molecules, is often hampered by random attachment of PSA molecules onto the 
protein. As a result, attached PSA can mask the active site of the therapeutic. 
In many cases, masking of activity can lead to complete loss of the protein's 
therapeutic function. 
 
 
To avoid such problems, polysialylation is targeted on a specific domain on the 
protein, away from the active site. To that end, a specific domain is created by 
the introduction of a cysteine on the protein molecule (away from the active 
site) through protein engineering. 
 
 
The US granted patent refers to the preparation of the 
PSA-linker-SH (cysteine)-protein construct. It has been shown that a number of 
therapeutic proteins which have been polysialylated, retain most of their 
activity as well as all the advantages of polysialylation i.e. improved drug 
performance and longer circulation time of the drug in the body. 
 
 
In summary, the patent identifies that polysialylation, Lipoxen's PolyXen 
platform, is more effective in improving the therapeutic function of protein 
drugs. 
 
 
Commenting on the patent grant, M. Scott Maguire, CEO of Lipoxen, said: "The new 
patent grant on this natural polymer which extends the active life of protein 
enhances our patent position in the world's largest pharmaceutical market and 
further supports our drive to become a leading innovator within the next 
generation biologic drug space. 
 
 
Lipoxen has two potential billion dollar block-buster products in clinical 
development, SuliXen, a long acting insulin and ErepoXen, a long-acting 
erythropoietin (EPO) both of which are based on this PolyXen technology. We are 
confident that this new patent will strengthen our commercial position as well 
as our capability to collaborate with partners." 
 
 
- Ends - 
 
 
For further information please contact: 
 
 
+-------------------------------------------------+-------------------------+ 
| Lipoxen plc                                     |    +44 (0)20 7389 5015  | 
+-------------------------------------------------+-------------------------+ 
| M. Scott Maguire, Chief Executive Officer       |                         | 
+-------------------------------------------------+-------------------------+ 
|                                                 |                         | 
+-------------------------------------------------+-------------------------+ 
| Singer Capital Markets (nominated adviser)      |     +44 (0)20 3205 7500 | 
+-------------------------------------------------+-------------------------+ 
| Jeff Keating, Claes Spång                       |                         | 
+-------------------------------------------------+-------------------------+ 
|                                                 |                         | 
+-------------------------------------------------+-------------------------+ 
| Noble & Company                                 |    +44 (0)20 7763 2200  | 
+-------------------------------------------------+-------------------------+ 
| James Bromhead, Sam Reynolds                    |                         | 
+-------------------------------------------------+-------------------------+ 
|                                                 |                         | 
+-------------------------------------------------+-------------------------+ 
| Buchanan Communications                         |     +44 (0)20 7466 5000 | 
+-------------------------------------------------+-------------------------+ 
| Lisa Baderoon, Catherine Breen                  |                         | 
+-------------------------------------------------+-------------------------+ 
 
 
Notes for Editors 
 
 
About Lipoxen 
Lipoxen plc is a biopharmaceutical company focused on the development of new and 
improved biologic drugs and vaccines. Lipoxen has three proprietary patented 
technology platforms: 
 
 
1) PolyXen - for extending the efficacy and half life of biologic drugs 
2) ImuXen - for creating new vaccines and improving existing vaccines 
3) SiRNAblate - for the delivery of siRNA 
 
 
Lipoxen's technology is designed to improve the efficacy, safety, stability, 
biological half-life and immunologic characteristics of its products. 
 
 
Lipoxen has multiple drug and vaccine programmes in development. Two products 
are in clinical development, SuliXen, a long acting insulin and ErepoXen, a 
long-acting erythropoietin (EPO). Lipoxen's preclinical pipeline includes 
vaccines against HIV, influenza and malaria and an exclusive license deal with 
Baxter Healthcare for Factor VIII 
 
 
The Company has a low-risk business model and out-licenses its proprietary 
technologies to biopharmaceutical companies that have strong manufacturing and 
marketing capabilities. Lipoxen currently has commercial agreements with some of 
the world's leading biotechnology and pharmaceutical companies including Baxter, 
Schering-Plough, the Serum Institute of India Limited, Genentech, Amgen and 
Genzyme. Furthermore, Baxter, the Company's third largest shareholder, and 
management led the GBP2.9 million fundraising that the Company announced in May 
2009 . 
 
 
Lipoxen, which was founded in 1997, now trades on the AIM Market of the London 
Stock Exchange under the ticker symbol LPX. More information can be found at the 
Company's website: www.lipoxen.com. 
 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 MSCDXLFFBFFZBBL
Lipoxen (LSE:LPX)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Lipoxen Charts.
Lipoxen (LSE:LPX)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Lipoxen Charts.